Post Traumatic Stress Disorder (PTSD)

Also known as: Stress Disorder, Post Traumatic / Post Traumatic Stress Disorders / Post Traumatic Stress Disorder, PTSD / Post Traumatic Stress Disorder PTSD / Post Traumatic Stress Disorder / Post-Traumatic Stress Disorders / Stress Disorders, Post-Traumatic / Stress Disorder, Post-Traumatic / Post-Traumatic Stress Disorder (PTSD) / Posttraumatic Stress Disorder (PTSD) / Post-Traumatic Stress Disorder / PTSD, Post Traumatic Stress Disorder / PTSD / Stress Disorders, Post Traumatic / PTSD - Post Traumatic Stress Disorder / Traumatic neurosis / Post-traumatic stress disorder, unspecified

DrugDrug NameDrug Description
DB00215CitalopramCitalopram belongs to a class of antidepressant agents known as selective _serotonin-reuptake inhibitors_ (SSRIs) and is widely used to treat the symptoms of depression. Its chemical structure is unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other prescribed antidepressants [FDA label]. Citalopram is also known as _Celexa_, and available in tablet and solution forms [FDA label]. This drug was initially approved by the FDA in 1998 [L5230].
DB01175EscitalopramEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
DB00458ImipramineImipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively [A6584]. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. Imipramine may be used to treat depression and nocturnal enuresis in children [FDA Label]. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD) [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
DB00334OlanzapineOlanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.
DB00715ParoxetineParoxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize ⍺- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.
DB00457PrazosinPrazosin is a selective α-1-adrenergic receptor antagonist used to treat hypertension. It has also been used to decrease urinary obstruction and relieve symptoms associated with symptomatic benign prostatic hyperplasia. α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland. Prazosin has also been used in conjunction with cardiac glycosides and diuretics in the management of severe congestive heart failure. It has also been used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
DB01224QuetiapineQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
DB01104SertralineSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake [T28]. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects [A1844]. Sertraline displays a better safety or tolerability profile than other classes of antidepressants [A1846]. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants or monoamine oxidase inhibitors [T28]. Sertraline has shown therapeutic effectiveness as a treatment for major depressive disorder [A1836], obsessive-compulsive disorder (OCD) [A1838], panic disorder, post-traumatic stress disorder (PTSD) [A1841], premenstrual dysphoric disorder (PMDD) [A1842] and social anxiety disorder (social phobia).
DrugDrug NameTargetType
DB00215CitalopramSodium-dependent serotonin transportertarget
DB00215CitalopramCytochrome P450 2C19enzyme
DB00215CitalopramCytochrome P450 2D6enzyme
DB00215CitalopramCytochrome P450 3A4enzyme
DB00215CitalopramMultidrug resistance protein 1transporter
DB00215CitalopramCytochrome P450 1A2enzyme
DB00215CitalopramHistamine H1 receptortarget
DB01175EscitalopramSodium-dependent serotonin transportertarget
DB01175EscitalopramCytochrome P450 3A4enzyme
DB01175EscitalopramCytochrome P450 2D6enzyme
DB01175EscitalopramSodium-dependent dopamine transportertarget
DB01175EscitalopramSodium-dependent noradrenaline transportertarget
DB01175EscitalopramAlpha-1A adrenergic receptortarget
DB01175EscitalopramMuscarinic acetylcholine receptor M1target
DB01175EscitalopramHistamine H1 receptortarget
DB01175EscitalopramCytochrome P450 2C19enzyme
DB00458ImipramineSodium-dependent noradrenaline transportertarget
DB00458ImipramineSodium-dependent serotonin transportertarget
DB00458ImipramineCytochrome P450 1A2enzyme
DB00458ImipramineCytochrome P450 2C19enzyme
DB00458ImipramineCytochrome P450 2D6enzyme
DB00458ImipramineHistamine H1 receptortarget
DB00458ImipramineAlpha-1A adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 2Atarget
DB00458ImipramineMuscarinic acetylcholine receptor M1target
DB00458ImipramineMuscarinic acetylcholine receptor M2target
DB00458ImipramineMuscarinic acetylcholine receptor M3target
DB00458ImipramineMuscarinic acetylcholine receptor M4target
DB00458ImipramineMuscarinic acetylcholine receptor M5target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 2target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 3target
DB00458ImipramineAlpha-1D adrenergic receptortarget
DB00458ImipramineAlpha-1-acid glycoprotein 1carrier
DB00458ImipramineSolute carrier family 22 member 2transporter
DB00458ImipramineSolute carrier family 22 member 3transporter
DB00458ImipramineMultidrug resistance protein 1transporter
DB00458ImipramineSolute carrier family 22 member 4transporter
DB00458ImipramineCytochrome P450 3A4enzyme
DB00458ImipramineCytochrome P450 2B6enzyme
DB00458ImipramineCytochrome P450 2C18enzyme
DB00458ImipramineCytochrome P450 2E1enzyme
DB00458ImipramineCytochrome P450 3A7enzyme
DB00458Imipramine5-hydroxytryptamine receptor 2Ctarget
DB00458ImipramineAlpha-1B adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 7target
DB00458ImipramineD(1) dopamine receptortarget
DB00458ImipramineD(2) dopamine receptortarget
DB00458ImipraminePotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent dopamine transportertarget
DB00458Imipramine5-hydroxytryptamine receptor 1Atarget
DB00458Imipramine5-hydroxytryptamine receptor 6target
DB00458ImipraminePotassium voltage-gated channel subfamily H member 1target
DB00458ImipramineSerum albumincarrier
DB00458ImipramineAlpha-1-acid glycoprotein 2target
DB00334OlanzapineMuscarinic acetylcholine receptor M5target
DB00334OlanzapineD(1A) dopamine receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M1target
DB00334OlanzapineMuscarinic acetylcholine receptor M3target
DB00334Olanzapine5-hydroxytryptamine receptor 2Atarget
DB00334OlanzapineD(4) dopamine receptortarget
DB00334OlanzapineHistamine H1 receptortarget
DB00334OlanzapineMuscarinic acetylcholine receptor M4target
DB00334OlanzapineMuscarinic acetylcholine receptor M2target
DB00334OlanzapineD(2) dopamine receptortarget
DB00334Olanzapine5-hydroxytryptamine receptor 2Ctarget
DB00334OlanzapineD(3) dopamine receptortarget
DB00334OlanzapineAlpha-1B adrenergic receptortarget
DB00334OlanzapineCytochrome P450 1A2enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 1Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Btarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Dtarget
DB00334Olanzapine5-hydroxytryptamine receptor 1Etarget
DB00334Olanzapine5-hydroxytryptamine receptor 3Atarget
DB00334Olanzapine5-hydroxytryptamine receptor 6target
DB00334Olanzapine5-hydroxytryptamine receptor 7target
DB00334OlanzapineAlpha-1A adrenergic receptortarget
DB00334OlanzapineAlpha-2A adrenergic receptortarget
DB00334OlanzapineAlpha-2B adrenergic receptortarget
DB00334OlanzapineAlpha-2C adrenergic receptortarget
DB00334OlanzapineD(1B) dopamine receptortarget
DB00334OlanzapineSerum albumincarrier
DB00334OlanzapineAlpha-1-acid glycoprotein 1carrier
DB00334OlanzapineDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00334OlanzapineCytochrome P450 2D6enzyme
DB00334OlanzapineMultidrug resistance protein 1transporter
DB00334OlanzapineCytochrome P450 2C19enzyme
DB00334OlanzapineCytochrome P450 3A4enzyme
DB00334Olanzapine5-hydroxytryptamine receptor 2Btarget
DB00334Olanzapine5-hydroxytryptamine receptor 5Atarget
DB00334OlanzapineD(1) dopamine receptortarget
DB00334OlanzapineHistamine H2 receptortarget
DB00334OlanzapineHistamine H4 receptortarget
DB00334OlanzapineGABA-A receptor (anion channel)target
DB00334OlanzapineBeta adrenergic receptortarget
DB00334OlanzapineD(2L) dopamine receptortarget
DB00334OlanzapineD(2S) dopamine receptortarget
DB00334OlanzapineUDP-glucuronosyltransferase 1-1enzyme
DB00715ParoxetineSodium-dependent serotonin transportertarget
DB00715ParoxetineSodium-dependent noradrenaline transportertarget
DB00715Paroxetine5-hydroxytryptamine receptor 2Atarget
DB00715ParoxetineCytochrome P450 2D6enzyme
DB00715ParoxetineMuscarinic acetylcholine receptor M1target
DB00715ParoxetineMuscarinic acetylcholine receptor M2target
DB00715ParoxetineMuscarinic acetylcholine receptor M3target
DB00715ParoxetineMuscarinic acetylcholine receptor M4target
DB00715ParoxetineMuscarinic acetylcholine receptor M5target
DB00715ParoxetineCytochrome P450 2C9enzyme
DB00715ParoxetineMultidrug resistance protein 1transporter
DB00715ParoxetineCytochrome P450 2B6enzyme
DB00715ParoxetineCytochrome P450 2C8enzyme
DB00715ParoxetineCytochrome P450 1A2enzyme
DB00715ParoxetineCytochrome P450 3A4enzyme
DB00457PrazosinAlpha-1A adrenergic receptortarget
DB00457PrazosinAlpha-1B adrenergic receptortarget
DB00457PrazosinAlpha-1D adrenergic receptortarget
DB00457PrazosinPotassium voltage-gated channel subfamily H member 2target
DB00457PrazosinPotassium voltage-gated channel subfamily H member 6target
DB00457PrazosinPotassium voltage-gated channel subfamily H member 7target
DB00457PrazosinAlpha-1-acid glycoprotein 1carrier
DB00457PrazosinSolute carrier family 22 member 2transporter
DB00457PrazosinSolute carrier family 22 member 1transporter
DB00457PrazosinSolute carrier family 22 member 3transporter
DB00457PrazosinMultidrug resistance protein 1transporter
DB00457PrazosinATP-binding cassette sub-family G member 2transporter
DB00457PrazosinCytochrome P450 1A1enzyme
DB00457PrazosinAlpha-2A adrenergic receptortarget
DB00457PrazosinAlpha-2B adrenergic receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 2Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 2Ctarget
DB01224QuetiapineD(2) dopamine receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Atarget
DB01224QuetiapineHistamine H1 receptortarget
DB01224QuetiapineCytochrome P450 3A4enzyme
DB01224QuetiapineAlpha-1A adrenergic receptortarget
DB01224QuetiapineAlpha-1B adrenergic receptortarget
DB01224QuetiapineAlpha-1D adrenergic receptortarget
DB01224QuetiapineAlpha-2A adrenergic receptortarget
DB01224QuetiapineAlpha-2B adrenergic receptortarget
DB01224QuetiapineAlpha-2C adrenergic receptortarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Dtarget
DB01224QuetiapineMuscarinic acetylcholine receptor M1target
DB01224QuetiapineMuscarinic acetylcholine receptor M2target
DB01224QuetiapineMuscarinic acetylcholine receptor M3target
DB01224QuetiapineMuscarinic acetylcholine receptor M4target
DB01224QuetiapineMuscarinic acetylcholine receptor M5target
DB01224Quetiapine5-hydroxytryptamine receptor 1Btarget
DB01224Quetiapine5-hydroxytryptamine receptor 1Etarget
DB01224Quetiapine5-hydroxytryptamine receptor 3Atarget
DB01224Quetiapine5-hydroxytryptamine receptor 6target
DB01224Quetiapine5-hydroxytryptamine receptor 7target
DB01224QuetiapineD(1B) dopamine receptortarget
DB01224QuetiapineD(1A) dopamine receptortarget
DB01224QuetiapineD(3) dopamine receptortarget
DB01224QuetiapineD(4) dopamine receptortarget
DB01224QuetiapineCytochrome P450 3A5enzyme
DB01224QuetiapineCytochrome P450 3A7enzyme
DB01224QuetiapineMultidrug resistance protein 1transporter
DB01224QuetiapineCytochrome P450 2C19enzyme
DB01224QuetiapineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent serotonin transportertarget
DB01104SertralineCytochrome P450 2B6enzyme
DB01104SertralineCytochrome P450 2C19enzyme
DB01104SertralineCytochrome P450 2C9enzyme
DB01104SertralineCytochrome P450 2D6enzyme
DB01104SertralineSodium-dependent dopamine transportertarget
DB01104SertralineCYP2B proteinenzyme
DB01104SertralineCytochrome P450 3A4enzyme
DB01104SertralineAmine oxidase [flavin-containing] Benzyme
DB01104SertralineAmine oxidase [flavin-containing] Aenzyme
DB01104SertralineMultidrug resistance protein 1transporter
DB01104SertralineSerum albumincarrier
DB01104SertralineSigma receptortarget
DrugDrug NamePhaseStatusCount
DB00422Methylphenidate0Completed1
DB00107Oxytocin0Completed1
DB00590Doxazosin1Recruiting1
DB01018Guanfacine1Completed1
DB01221Ketamine1Recruiting1
DB05096LY21400231Terminated1
DB11889Lanicemine1Recruiting1
DB01454Midomafetamine1Recruiting1
DB00834Mifepristone1Completed1
DB00627Niacin1Recruiting1
DB00790Perindopril1Recruiting1
DB00740Riluzole1Recruiting1
DB09061Cannabidiol1 / 2Not Yet Recruiting1
DB00590Doxazosin1 / 2Recruiting1
DB14009Medical Cannabis1 / 2Active Not Recruiting1
DB00486Nabilone1 / 2Active Not Recruiting1
DB00571Propranolol1 / 2Active Not Recruiting1
DB00740Riluzole1 / 2Unknown Status1
DB00734Risperidone1 / 2Completed1
DB01104Sertraline1 / 2Completed1
DB06151Acetylcysteine2Completed1
DB06151Acetylcysteine2Recruiting2
DB01238Aripiprazole2Completed1
DB00335Atenolol2Recruiting1
DB01076Atorvastatin2Terminated1
DB09128Brexpiprazole2Completed1
DB09128Brexpiprazole2Terminated1
DB00921Buprenorphine2Not Yet Recruiting1
DB00921Buprenorphine2Recruiting1
DB09061Cannabidiol2Recruiting1
DB01136Carvedilol2Unknown Status1
DB00260Cycloserine2Unknown Status2
DB00590Doxazosin2Recruiting2
DB05087Ganaxolone2Completed1
DB04946Iloperidone2Completed1
DB01221Ketamine2Completed1
DB01221Ketamine2Recruiting1
DB00125L-Arginine2Unknown Status1
DB00678Losartan2Recruiting1
DB00683Midazolam2Completed1
DB01454Midomafetamine2Completed1
DB01454Midomafetamine2Recruiting1
DB00834Mifepristone2Completed1
DB00834Mifepristone2Recruiting1
DB00704Naltrexone2Not Yet Recruiting1
DB00704Naltrexone2Recruiting1
DB12979Nepicastat2Completed1
DB00325Nitroprusside2Recruiting1
DB06690Nitrous oxide2Recruiting1
DB12427Orvepitant2Completed1
DB00107Oxytocin2Completed2
DB00107Oxytocin2Enrolling by Invitation1
DB12012PF-044578452Terminated1
DB00715Paroxetine2Terminated1
DB00388Phenylephrine2Recruiting1
DB00457Prazosin2Recruiting1
DB02789Pregnenolone2Withdrawn1
DB00571Propranolol2Completed2
DB00571Propranolol2Recruiting2
DB01104Sertraline2Completed3
DB01104Sertraline2Terminated1
DB09153Sodium chloride2Completed1
DB09072Sodium oxybate2Withdrawn1
DB00273Topiramate2Not Yet Recruiting1
DB01273Varenicline2Completed1
DB12436Vofopitant2Completed1
DB01392Yohimbine2Completed1
DB00246Ziprasidone2Terminated1
DB00909Zonisamide2Recruiting2
DB00404Alprazolam2 / 3Completed1
DB01156Bupropion2 / 3Completed1
DB00260Cycloserine2 / 3Completed1
DB00260Cycloserine2 / 3Recruiting1
DB00260Cycloserine2 / 3Unknown Status1
DB01221Ketamine2 / 3Recruiting1
DB01221Ketamine2 / 3Withdrawn1
DB01202Levetiracetam2 / 3Completed1
DB00683Midazolam2 / 3Recruiting1
DB00683Midazolam2 / 3Withdrawn1
DB00184Nicotine2 / 3Completed1
DB00396Progesterone2 / 3Recruiting1
DB00734Risperidone2 / 3Completed1
DB01104Sertraline2 / 3Completed1
DB09128Brexpiprazole3Terminated1
DB00924Cyclobenzaprine3Terminated1
DB01151Desipramine3Completed1
DB00472Fluoxetine3Completed1
DB00555Lamotrigine3Withdrawn1
DB00704Naltrexone3Completed1
DB00715Paroxetine3Completed3
DB00413Pramipexole3Recruiting1
DB00457Prazosin3Completed2
DB00230Pregabalin3Recruiting1
DB01224Quetiapine3Completed1
DB01104Sertraline3Completed1
DB01104Sertraline3Terminated1
DB00273Topiramate3Withdrawn1
DB00313Valproic Acid3Completed1
DB01068Clonazepam4Completed1
DB00260Cycloserine4Completed1
DB01234Dexamethasone4Completed1
DB00590Doxazosin4Completed1
DB01175Escitalopram4Completed1
DB00783Estradiol4Recruiting1
DB00402Eszopiclone4Completed1
DB00502Haloperidol4Completed1
DB00741Hydrocortisone4Withdrawn1
DB01235Levodopa4Completed1
DB01043Memantine4Completed1
DB06148Mianserin4Active Not Recruiting1
DB00834Mifepristone4Completed1
DB01017Minocycline4Recruiting1
DB00370Mirtazapine4Completed2
DB00704Naltrexone4Completed1
DB00107Oxytocin4Active Not Recruiting1
DB00715Paroxetine4Completed6
DB00715Paroxetine4Terminated1
DB00457Prazosin4Completed2
DB00571Propranolol4Completed1
DB00571Propranolol4Terminated1
DB00571Propranolol4Unknown Status1
DB01224Quetiapine4Completed3
DB00734Risperidone4Completed1
DB01104Sertraline4Completed7
DB01104Sertraline4Terminated1
DB09153Sodium chloride4Active Not Recruiting1
DB00273Topiramate4Completed3
DB00273Topiramate4Recruiting1
DB00193Tramadol4Unknown Status1
DB00313Valproic Acid4Terminated1
DB00285Venlafaxine4Completed1
DB06684Vilazodone4Completed1
DB09068Vortioxetine4Recruiting1
DB00246Ziprasidone4Completed1
DB00921BuprenorphineNot AvailableCompleted1
DB01156BupropionNot AvailableCompleted1
DB00260CycloserineNot AvailableCompleted1
DB01234DexamethasoneNot AvailableCompleted1
DB00470DronabinolNot AvailableRecruiting1
DB00476DuloxetineNot AvailableActive Not Recruiting1
DB01175EscitalopramNot AvailableCompleted3
DB00472FluoxetineNot AvailableActive Not Recruiting1
DB00741HydrocortisoneNot AvailableCompleted2
DB00741HydrocortisoneNot AvailableRecruiting1
DB00741HydrocortisoneNot AvailableUnknown Status1
DB00741HydrocortisoneNot AvailableWithdrawn1
DB01221KetamineNot AvailableCompleted2
DB01221KetamineNot AvailableRecruiting2
DB00186LorazepamNot AvailableUnknown Status1
DB00834MifepristoneNot AvailableCompleted1
DB01183NaloxoneNot AvailableCompleted1
DB00184NicotineNot AvailableRecruiting1
DB00107OxytocinNot AvailableUnknown Status1
DB05596PRX-03140Not AvailableCompleted1
DB00715ParoxetineNot AvailableActive Not Recruiting1
DB00715ParoxetineNot AvailableCompleted1
DB00715ParoxetineNot AvailableTerminated1
DB00715ParoxetineNot AvailableWithdrawn1
DB00457PrazosinNot AvailableCompleted3
DB00457PrazosinNot AvailableTerminated3
DB00457PrazosinNot AvailableUnknown Status2
DB00635PrednisoneNot AvailableCompleted1
DB02789PregnenoloneNot AvailableCompleted1
DB00571PropranololNot AvailableRecruiting1
DB01224QuetiapineNot AvailableCompleted2
DB09153Sodium chlorideNot AvailableRecruiting1
DB00273TopiramateNot AvailableTerminated1
DB00285VenlafaxineNot AvailableActive Not Recruiting1